European Respiratory Society and European Sleep Research Society statement on the treatment of central sleep apnoea with adaptive servo-ventilation.

However, after the publication of the SERVE-HF study, its use was restricted in patients with systolic heart failure (HF) and prevalent CSA, and was withheld from many patients with symptomatic CSA.

然而，在SERVE-HF研究发表后，其使用在收缩性心力衰竭（HF）和常见CSA的患者中受到限制，并且许多有症状的CSA患者被禁止使用。

In the meantime, the devices have been further developed and the algorithms adapted, and there is new evidence from randomised controlled trials and observational studies that makes it necessary to re-evaluate some societies' statements on the use of ASV, especially in patients with HF and CSA and with the current ASV devices.

与此同时，设备已经进一步开发，算法也已适应，有新的来自随机对照试验和观察性研究的证据表明，有必要重新评估一些学会关于使用ASV的声明，特别是在心力衰竭（HF）和中枢性睡眠呼吸暂停（CSA）患者中，以及使用当前的ASV设备。

This short statement is based on a review of the effect of ASV on hard cardiovascular end-points, echocardiographic parameters and exercise capacity as well as on sleep architecture and sleep quality, symptoms and quality of life (QoL) in patients with congestive HF.

这份简短的声明是基于对ASV对硬性心血管终点、超声心动图参数和运动能力以及睡眠结构和睡眠质量、症状和生活质量（QoL）的影响的回顾，这些影响是在充血性心力衰竭患者中观察到的。

The expert group concludes that ASV has positive effects on CSA and QoL in various forms of CSA, that current ASV devices have no negative effect on hard cardiovascular end-points, and that ASV has positive effects on patient-reported outcomes.

专家组得出结论，自动同步呼吸（ASV）对各种形式的中枢性睡眠呼吸暂停（CSA）的呼吸暂停低通气指数（AHI）和生活质量（QoL）有积极影响，目前的ASV设备对硬性心血管终点事件没有不良影响，并且ASV对患者报告的结局有积极效果。

Moreover, it is used by Task Force members after optimal treatment of the underlying disease and after an unsuccessful continuous positive airway pressure trial in patients with HF with preserved ejection fraction, but also in patients with left ventricular ejection fraction 30-45%.

此外，ASV在优化基础疾病治疗后以及在射血分数保留的心力衰竭患者中连续正压通气（CPAP）试验失败后，以及在左心室射血分数为30-45%的患者中，也被任务组成员使用。

In the latter group, however, initiation is performed in expert centres only.

然而，在后一组中，仅在专业中心进行启动。

In severe systolic HF, ASV is sometimes evaluated in a palliative therapy concept for severely symptomatic patients with CSA.

在严重的收缩性心力衰竭中，对于有中枢性睡眠呼吸暂停（CSA）的严重症状患者，有时会在姑息治疗概念中评估使用ASV。